[(1S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[acetyl(methyl)amino]propanoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: [(1S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[acetyl(methyl)amino]propanoate
• 化学式: C₃₄H₄₆ClN₃O₁₀
• 分子量: 692.2
• InChiKey: WKPWGQKGSOKKOO-KWNYJYNBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  48
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  157
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• COMPOUNDS AND METHODS FOR THE TREATMENT OF EGFR POSITIVE DISEASES
  申请人：Bio-Thera Solutions, Ltd., Co.

  公开号：US20140178412A1

  公开（公告）日：2014-06-26

  Disclosed herein are anti-EGFR antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat EGFR positive cells in cancers are provided.

  本文披露了与马替南素类药物结合的抗EGFR抗体，用于靶向输送至疾病组织。提供了与制备和使用这种抗体药物结合物相关的方法，用于治疗癌症中的EGFR阳性细胞。
• COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES
  申请人：Bio-Thera Solutions, Ltd., Co.

  公开号：US20170258935A1

  公开（公告）日：2017-09-14

  Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.
• US8889855B2
  申请人：——

  公开号：US8889855B2

  公开（公告）日：2014-11-18
• US9314536B2
  申请人：——

  公开号：US9314536B2

  公开（公告）日：2016-04-19